Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as aprimary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society ofGynecologic Oncology support the ...
Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as aprimary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society ofGynecologic Oncology support the following scientific facts:• Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervicalintraepithelial neoplasia.
• Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the currentcytology method.
• The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in thisage, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening intervalshould be no sooner than every 3 years and no longer than every 5 years.
• Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPVscreening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, andscreening interval.